COMBINATION THERAPY FOR NON-SMALL CELL LUNG CANCER POSITIVE FOR EGFR MUTATION

• 1. 非小细胞肺癌EGFR突变阳性的联合疗法 [P] . 中国专利： CN107530434A . 2018-01-02
• 2. 紫杉醇联合参一胶囊与EGFR-TKIs在制备治疗EGFR突变阳性NSCLC药物中的应用 [P] . 中国专利： CN104306386A . 2015-01-28
• 3. COMBINATION THERAPY FOR NON-SMALL CELL LUNG CANCER POSITIVE FOR EGFR MUTATION [P] . 美国专利： US2018147279A1 . 2018-05-31

  机译： 非小细胞肺癌EGFR突变阳性的联合治疗

• 4. COMBINATION THERAPY FOR NON-SMALL CELL LUNG CANCER POSITIVE FOR EGFR MUTATION [P] . 欧洲知识产权局专利： EP3285804A1 . 2018-02-28

  机译： 非小细胞肺癌EGFR突变阳性的联合治疗

• 5. Combination therapy of non-small cell lung cancer positive for EGFR gene mutation [P] . 日本专利： JP2018513178A . 2018-05-24

  机译： EGFR基因突变阳性的非小细胞肺癌联合治疗

• 1. The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations [J] . Hidekazu Suzuki, Tomonori Hirashima, Norio Okamoto, 癌症（英文版） . 2013,第003期
• 2. EGFR tyrosine kinase inhibitor HS-10182 increases radiation sensitivity in non-small cell lung cancers with EGFR T790M mutation [J] . Yang Chen, Youyou Wang, Lujun Zhao, 癌症生物学与医学：英文版 . 2018,第001期
• 3. EGFR tyrosine kinase inhibitor HS-10182 increases radiation sensitivity in non-small cell lung cancers with EGFR T790M mutation [J] . Yang Chen, Youyou Wang, Lujun Zhao, 癌症生物学与医学：英文版 . 2018,第001期
• 4. EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer [J] . Tomoaki Sonoda, Shingo Nishikawa, Rie Sakakibara, Respiratory Medicine Case Reports . 2018,第4期
• 5. A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease [J] . MarianoC., BosdetI., KarsanA., Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2014,第1期
• 6. A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease [J] . MarianoC., BosdetI., KarsanA., Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2014,第1期
• 7. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016
• 8. Application of Quantitative Metrics for EGFR-Targeted Non-Small Cell Lung Cancer Therapy Using [11C]Erlotinib PET. [D] . Petrulli, Joseph Ryan. 2017
• 9. A Real-World Observational Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The ‘LUNGFUL’ Study [O] . Giannis Mountzios, Anna Koumarianou, Alexandros Bokas, 2021
• 10. EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer [O] . Tomoaki Sonoda, Shingo Nishikawa, Rie Sakakibara, 2018

• 1. Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population [J] . Noorwati SUTANDYO ,Arif HANAFI ,Mulawarman JAYUSMAN . 中国肺癌杂志 . 2019,第009期
• 2. Efficacy of EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients Harboring Different Types of EGFR Mutations: A Retrospective Analysis [J] . Hua-li LIU ,Guang HAN ,Min PENG . 华中科技大学学报（医学）（英德文版） . 2017,第006期
• 3. 非小细胞肺癌中EGFR突变阳性患者绝经状态与EGFR-TKI疗效的关系 [C] . 殷靖宜 ,安社娟 ,严红虹 . 第13届全国肺癌学术大会 . 2013
• 4. 第一部分 非小细胞肺癌EGFR基因突变类型和突变量与TKI疗效的关系；第二部分 术后复发的非小细胞肺癌EGFR罕见突变患者临床特点与TKI疗效的关系 [A] . 杨文静 . 2015